Inventor · disambiguated record
Atsuhiko Kato
Also filed as: KATO ATSUHIKO
13 granted patents·7 pending applications·55 citations·filing 2000–2023
88Inventor score
Files withCHUGAI PHARMACEUTICAL CO LTD12YAMAZAKI TATSUMI2ABURATANI HIROYUKI1CHUGAI SEI YAKU KABUSHIKI KAIS1KATAOKA HIROAKI1
Top patents by PatentIndex Score
20 records- 0188US11780912B2Composition for prophylaxis or treatment of IL-8 related diseasesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Oct 10, 2023·3 cites·12 claims
- 0285US11053308B2Method for treating IL-8-related diseasesCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Jul 6, 2021·7 cites·9 claims
- 0385US6500854B1Chondrongenesis promotors and indolin-2-one derivativesCHUGAI SEI YAKU KABUSHIKI KAIS·Filed 2000·Granted Dec 31, 2002·27 cites·18 claims
- 0480US8663929B2Method for detection of liver cancer cell using anti-glypican-3 antibodyKATAOKA HIROAKI·Filed 2009·Granted Mar 4, 2014·9 cites·12 claims
- 0579US11767362B1Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Sep 26, 2023·2 cites·8 claims
- 0679US9556264B2Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Jan 31, 2017·5 cites·25 claims
- 0772US2023085803A1Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted thereinCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0869US11858987B2Cancer stem cell-specific moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Jan 2, 2024·0 cites·17 claims
- 0964US2024026006A1Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1063US6716628B2Chondrogenesis promoters and indolin-2-one derivativesCHUGAI PHARMACEUTICAL CO LTD·Filed 2002·Granted Apr 6, 2004·2 cites·21 claims
- 1162US11965180B2Cancer stem cell population and method for production thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Apr 23, 2024·0 cites·4 claims
- 1259US10934351B2Cancer stem cell-specific moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted Mar 2, 2021·0 cites·22 claims
- 1353US2014302511A1Cancer stem cell-specific moleculePHARMALOGICALS RES PTE LTD·Filed 2012·Application pending·0 cites
- 1451US10018630B2Cancer stem cell isolationYAMAZAKI TATSUMI·Filed 2012·Granted Jul 10, 2018·0 cites·8 claims
- 1550US11536713B2Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted thereinSUZUKI MASAMI·Filed 2010·Granted Dec 27, 2022·0 cites·6 claims
- 1643US2008008710A1Therapeutic Agent And Diagnostic Agent For CholangiocarcinomaABURATANI HIROYUKI·Filed 2004·Application pending·0 cites
- 1743US2017129950A1Humanized Anti-Epiregulin Antibody, and Cancer Therapeutic Agent Comprising Said Antibody as Active IngredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 1841US11124773B2Cancer stem cell population and method for production thereofYAMAZAKI TATSUMI·Filed 2011·Granted Sep 21, 2021·0 cites·5 claims
- 1941US2016159919A1Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding AdenocarcinomaCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Application pending·0 cites
- 2034US2003049211A1Remedies and preventives for dental diseasesFiled 2000·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Atsuhiko Kato files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →